FDA Inspection 1179443 — REDHILL BIOPHARMA INC.
The FDA completed an inspection of REDHILL BIOPHARMA INC. on Aug 25, 2022 in Raleigh, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 25, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Raleigh, NC (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)